Why IMU is a multi multi bagger, page-26828

In the new newsletter I'm pleased to read that all 4 patients enrolled in cohort B Azer-cell trial are still on the trial.

Two complete responses so far.

"Notably, all four patients enrolled in Cohort B had failed
four to five prior treatments, including autologous CAR T
therapy. All four patients remain on the study and given
the robust response rates and durability seen to date, the
company will continue to enrol patients in the azer-cel plus
IL-2 cohort and will closely follow all patients for further
responses and durability. Importantly, the therapy has
shown to be safe and tolerable in both cohorts."